Table 3 b.

Genetic Interactions of KIR and immunoglobulin allotypes in patients with HCV and HCV-DM.

GM Allotypes and KIR genes	HCV-DM n=32	HCV n=121	p* (OR; CI)
	n (%)	n (%)
2DS4+	15 (47)	50(41)	ns
2DS4−	17 (53)	71(59)	ns
ff+	5 (16)	21(17)	ns
ff−	27 (84)	100(83)	ns
KM3/KM3+	16 (50)	56(46)	ns
KM3/KM3−	16 (50)	65(54)	ns
2DS4(+) 2DL3/2DL3, 2DL1	8 (25)	21(17)	ns
2DS4(+) 2DL3/2DL3, 2DL1 ff+	3 (9)	3(2)	ns
2DS4(+) 2DL3/2DL3, 2DL1 ff−	5 (16)	18(15)	ns
2DS4(+) 2DL3/2DL3, 2DL1 3/3+	2 (6)	9(7)	ns
2DS4(+) 2DL3/2DL3, 2DL1 3/3−	6 (19)	12(10)	ns
2DS4(−) 2DL3/2DL3, 2DL1	13 (41)	22(18)	0.01 (3.07; 1.32–7.1)
2DS4(−) 2DL3/2DL3, 2DL1 ff+	1 (3)	5(4)	ns
2DS4(−) 2DL3/2DL3, 2DL1 ff−	12 (38)	17(14)	0.005 (3.67; 1.52–8.85)
2DS4(−) 2DL3/2DL3, 2DL1 3/3+	9 (28)	12(10)	0.01 (3.55; 1.34–9.41)
2DS4(−) 2DL3/2DL3, 3/3−	4 (13)	10(8)	ns

HCV-DM: Hepatitis C infected patients with type 2 diabetes; HCV Non-DM: Hepatitis C infected patients without type 2 diabetes Haplotype A fragment: KIR 2DL3/2DL3, 2DL2 (−), 2DS1 (−), 2DS2 (−) 2DL1, 2DS4

^p*p values analyzed by Fisher two tail exact method; OR= odds ratio; CI; confidence interval; ND: Not determined